Skip to content

Arrowhead Pharmaceuticals

US · ARWR #1569 by market cap Listed 1970
41.37 -2.28 -5.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $89.59 to $126
    Market Newswire · 2026/8/5
  • Rating change
    Goldman Sachs Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Cuts Target Price to $74
    Market Newswire · 2026/9/24
  • Rating change
    RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/8/31
  • Rating change
    A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $108 to $126
    Market Newswire · 2026/10/15
  • A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $96 to $126
    Market Newswire · 2026/11/14
  • Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $126
    Market Newswire · 2026/11/10
  • Rating change
    J.P. Morgan Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
    Market Newswire · 2026/10/15
  • Rating change
    BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/12
  • Rating change
    Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
    Market Newswire · 2026/9/16
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: CapsoVision, Inc. (CV), Arrowhead Pharmaceuticals (ARWR)
    TipRanks · 2026/8/31
  • Rating change
    J.P. Morgan Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $100
    Market Newswire · 2026/8/7
  • Rating change
    Citi Initiates Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $108
    Market Newswire · 2026/9/8
  • Rating change
    TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
    Market Newswire · 2026/8/31
  • Rating change
    Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/9/1
  • Stifel Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $96
    Market Newswire · 2026/11/13
  • Rating change
    Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $108
    Market Newswire · 2026/9/9
  • Rating change
    H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $120
    Market Newswire · 2026/8/7
  • H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/11/11
  • Rating change
    Stifel Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $104
    Market Newswire · 2026/8/31
  • B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $123
    Market Newswire · 2026/11/10
  • Rating change
    B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123
    Market Newswire · 2026/7/30
  • Rating change
    RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $100
    Market Newswire · 2026/7/31
  • Rating change
    B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $123
    Market Newswire · 2026/8/5
  • H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/10/16
  • Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $126
    Market Newswire · 2026/10/16

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arrowhead Pharmaceuticals discussion 0 comments

Add a comment